Grufity logo
Grufity logo
EYPT

EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

$4.25-0.09 (-2.07%)
Delayed as of 10 Sep 2026, 04:00 pm ET

EYPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYPT Price Action

Last 7 days

-7.0%

Last 30 days

-67.4%

Last 90 days

-67.4%

Trailing 12 Months

-68.6%

EYPT RSI Chart

EYPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYPT Valuation

Market Cap

366.4M

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

131.42

EV/EBITDA

-0.92

Price/Free Cashflow

-1.35

EYPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

-90.49%

Rev. Growth (Qtr)

-27.16%

EYPT Earnings

Earnings (TTM)

-306.6M

Earnings Growth (Yr)

-58.97%

Earnings Growth (Qtr)

-11.36%

EYPT Profitability

EBT Margin

-10077.40%

Return on Equity

-184.27%

Return on Assets

-134.38%

Free Cashflow Yield

-74.04%

EYPT Investor Care

Shares Dilution (1Y)

25.15%

Diluted EPS (TTM)

-3.75

EYPT Alerts

  • 1 major insider buys recently.
Revenue & Growth

How EyePoint Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20267.6M2.8M--
202556.0M51.9M42.3M31.4M
202450.0M50.4M45.7M43.3M
202339.8M37.3M42.5M46.0M
202238.9M41.5M42.4M41.4M
202134.3M39.2M32.5M36.9M
202025.8M22.8M35.9M34.4M
20195.7M12.2M14.2M20.4M
20182.9M3.0M3.1M4.6M
20176.1M7.5M7.6M2.6M
20167.9M1.6M3.1M4.6M
201526.4M26.6M20.3M14.1M
20143.7M3.5M28.2M28.1M
20132.4M2.1M2.2M2.2M
20126.5M3.5M2.4M2.4M
2011--6.1M6.4M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About EyePoint Pharmaceuticals Inc

EYPT
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://eyepointpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES144

EyePoint Pharmaceuticals Inc Frequently Asked Questions

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 10 2026, market cap of EyePoint Pharmaceuticals Inc is 366.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Sep 10 2026, EYPT's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 131.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.197 (multiply by 100 for percentage) rate of return.